Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

C’était l’histoire dont tout le monde parlait. En 2024, Novo Nordisk, grâce à ses traitements révolutionnaires contre l’obésité, s’imposait comme la première capitalisation boursière d’Europe, ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...

WEIGHT loss jabs are weaving themselves into the fabric of our daily lives and chances are you know someone taking them – or ...

European drug regulators classify NAION as a 'very rare' side effect of semaglutide — the active ingredient in Ozempic, Wegovy. The risk often emerged after two years of use ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

ACROSS the UK, waistlines are shrinking – and it’s not down to willpower alone. While Ozempic-like weight-loss jabs have been hailed as a breakthrough in helping tackle Britain’s obesity ...